Mesoblast Reports Fiscal 2026 Earnings, Reduced Net Loss, and RYONCIL Commercial Progress
Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, marking its first full year of commercial sales with the FDA-approved therapy RYONCIL. The company reduced its net loss by 44% to $57.5 million and ended the year with $103 million in cash. CEO Silviu Itescu highlighted strong fourth-quarter revenue performance at $36 million, while CFO Jim O'Brien noted a significant reduction in second-half cash burn from $50 million to $13.4 million. RYONCIL has achieved commercial traction with over 50 treatment centers onboarded and insurance coverage for more than 98% of U.S. lives. The company is also conducting a pivotal trial involving 180 adult patients with steroid-refractory acute GVHD, which could support label expansion if successful. Mesoblast expects double-digit revenue growth in the next year and has advanced its pipeline across Duchenne muscular dystrophy, chronic low back pain, and heart failure. The company received a J-code for RYONCIL in October 2025, aiding commercialization efforts. Real-world data showed an 84% early survival rate among treated children with acute GVHD.
Tickers: $MESO
Topics: biotech loss_reduction pharmaceuticals revenue_growth